Within the DS group, patients with active ABMR had higher CD19+ and HLA-II+ EVs both at first biopsy (n = 7) and at 12 months (n = 5) (Table 3 and Figures 2C,D). This evidence concerns the gene CD19 and Dravet syndrome.